Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewsWire • 02/02/23
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic AsthmaGlobeNewsWire • 01/17/23
Avalo Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/07/22
Wall Street Analysts Predict a 191% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should KnowZacks Investment Research • 09/07/22
Wall Street Analysts Predict a 230% Upside in Avalo Therapeutics, Inc. (AVTX): Here's What You Should KnowZacks Investment Research • 08/10/22
Avalo Reports Second Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/04/22
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)GlobeNewsWire • 08/02/22
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo TherapeuticsGlobeNewsWire • 08/01/22
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)GlobeNewsWire • 05/18/22
Avalo Therapeutics Reports 2021 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/02/22
Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor EventGlobeNewsWire • 01/06/22